Announcement • Apr 27
Kalaris Therapeutics, Inc., Annual General Meeting, Jun 03, 2026 Kalaris Therapeutics, Inc., Annual General Meeting, Jun 03, 2026. Announcement • Apr 05
Kalaris Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Kalaris Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Announcement • Dec 19
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naive Neovascular AMD Kalaris Therapeutics, Inc. announced positive initial data from its Phase 1a single ascending dose (SAD) trial of TH103, a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor, in treatment-naive patients with neovascular age-related macular degeneration (nAMD). The data demonstrate that TH103's engineered molecular properties translated into clinically meaningful improvements in vision and retinalomy, with early signals suggesting the potential for extended treatment durability. The initial data will be presented at 4:30 pm EST via webcast. TH103 was Engineered for Enhanced Potency and Intraocular Retention:vented by Dr. Napoleone Ferrara, Kalaris' scientific co-founder and current board member, whose pioneering research led to the development of the anti-VEGF class of therapies for retinal and oncology diseases, TH103 is an investigational anti-VEGF therapy specifically engineered to achieve extended intraocular retention with enhanced VEGF inhibition. In preclinical studies, TH103 demonstrated significantly enhanced binding to heparan sulfate proteoglycans (HSPG) and slower systemic clearance compared to aflibercept, supporting the hypothesis that these molecular characteristics could translate to extended durability. The Phase 1a trial evaluated a single intravitreal injection of TH103 at three dose levels (0.5 mg, 1.5 mg, 2.5 mg) in treatment-naive nAMD patients (N=13) who completed 6 months of follow-up. Results demonstrated robust visual and anatomic improvements that support TH103's molecular design and preclinical profile. Based on these results, Kalaris plans to use the drug product produced with the updated manufacturing process in its ongoing and planned clinical trials. Initial Phase 1a Data Provides Evidence TH103 May Offer Extended Treatment Durability: Pharmacokinetic Profile - Plasma levels of TH103 dose adjusted mean Cmax were 27 to 51-fold lower compared to current leading anti-VEGF agents, consistent with enhanced intraocular retention and reduced systemic exposure. Next steps in Clinical Development: Based on these positive initial Phase 1a data, Kalaris is accelerating its clinical development program. All statements, other than statements of historical fact, contained in this press release, including statements regarding the strategy, future operations, prospects, plans and objectives of management of Kalaris, including the therapeutic potential of TH103 for nAMD and other exudative and neovascular retinal diseases, the anticipated timelines for reporting clinical data from the Phase 1a and Phase 1b/2 clinical trials of TH103, plans to advance TH103 into Phase 3 clinical trials and to develop TH103 for additional indications and the sufficiency of Kalaris' cash resources for the period anticipated, are forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: risks associated with the clinical development and regulatory approval of TH103, including potential delays in the completion of clinical trials; expectations regarding the therapeutic benefits, clinical potential and clinical development of TH103; the timing of and Kalaris' ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials; risks related to the final results of the clinical trial or future trials; risks related To ensure that TH103 was engineered to enhance the treatment burden for the treatment durability. 
